Einfeldt, Mette Nygaard
Novo Nordisk (Denmark)
3 papers on CoChatORCID 0000-0003-2427-2601
Most cited papers
- Verified
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet
Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors
Cited by 386
- Verified
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Borlaug, B. A., Kitzman, D. W., Davies, M. J., Rasmussen, S., Barros, E., Butler, J., Einfeldt, M. N., Hovingh, G. K., Møller, D. V., Petrie, M. C., et al. (2023) · Nature Medicine
Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors
Cited by 215
- Verified
Semaglutide and NT-proBNP in Obesity-Related HFpEF
Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Shah, S. J., Verma, S., Jensen, T. J., Einfeldt, M. N., Liisberg, K., et al. (2024) · Journal of the American College of Cardiology
Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors
Cited by 95
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free